Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
42.97
-0.38 (-0.88%)
At close: Oct 16, 2025, 3:59 PM
42.97
0.00%
After-hours: Oct 16, 2025, 05:07 PM EDT
-0.88% (1D)
| Bid | 41.76 |
| Market Cap | 2.85B |
| Revenue (ttm) | 34K |
| Net Income (ttm) | -190.77M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -12.07 |
| Forward PE | -16.15 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 44.84 |
| Volume | 1,481,317 |
| Avg. Volume (20D) | 1,620,718 |
| Open | 43.24 |
| Previous Close | 43.35 |
| Day's Range | 41.98 - 44.80 |
| 52-Week Range | 8.24 - 44.80 |
| Beta | 0.40 |
| Ex-Dividend Date | n/a |
About MLYS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MLYS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MLYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+2.45%
Mineralys Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
-1.44%
MLYS stock has given up its prior gain. Mineralys Therapeutics shares were trading higher after the company announced it presented Launch-HTN data at ESH 2025 and demonstrated its efficacy for over 1,000 patients.
2 weeks ago · seekingalpha.com
Mineralys: Lorundrostat Continues To Deliver Hypertension Market ExpansionsMineralys Therapeutics, Inc. advances lorundrostat, its lead aldosterone inhibitor, for uncontrolled and resistant hypertension with pivotal Phase 3 successes. Mineralys achieved positive Phase 2 resu...
2 months ago · seekingalpha.com
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call TranscriptMineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jo...
